Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis

Arthritis and Rheumatism

Volumn 54, Issue 5, 2006, Pages 1435-1439

  Suissa, Samy ^a,b   Hudson, Marie ^a   Ernst, Pierre ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIMALARIAL AGENT; AZATHIOPRINE; CYCLOSPORIN; CYTOTOXIC AGENT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLD SALT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MINOCYCLINE; PENICILLAMINE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALAZOSULFAPYRIDINE;

ADULT; AGE; AGED; ARTICLE; CASE CONTROL STUDY; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA BASE; DISEASE SEVERITY; DRUG EFFECT; DRUG EXPOSURE; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; INTERSTITIAL LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COHORT STUDIES; FEMALE; HUMANS; ISOXAZOLES; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; RISK FACTORS;

EID: 33646479007     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.21806     Document Type: Article

References (14)

1. Cohen S, Cannon GW, Schiff M, Weaver A, Fox R, Olsen N, et al, for the Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Arthritis Rheum 2001;44:1984-92.
2. McCurry J. Japan deaths spark concerns over arthritis drug. Lancet 2004;363:461.
3. Sakai F, Noma S, Kurihara Y, Yamada H, Azuma A, Kudoh S, et al. Leflunomide-related lung injury in patients with rheumatoid arthritis. Mod Rheumatol 2005;15:173-9.
4. Kremer JM, Alarcon GS, Weinblatt ME, Kaymakcian MV, Macaluso M, Cannon GW, et al. Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review. Arthritis Rheum 1997;40:1829-37.
5. Saravanan V, Kelly CA. Reducing the risk of methotrexate pneumonitis in rheumatoid arthritis. Rheumatology (Oxford) 2004;43:143-7.
6. PharMetrics patient-centric database. Watertown (MA): PharMetrics, Inc. 2005.
7. Suissa S, Ernst P, Kezouh A, Bitton A, Hudson M. Newer disease modifying anti-rheumatic drugs (DMARDs) and the risk of serious hepatic adverse events in rheumatoid arthritis. Am J Med 2004;117:87-92.
8. Bernatsky S, Hudson M, Suissa S. Anti-rheumatic drug use and risk of hospitalization for congestive heart failure in rheumatoid arthritis. Rheumatology (Oxford) 2005;44:677-80.
9. Suissa S. Novel approaches to pharmacoepidemiological study design and statistical analysis. In: Strom B, editor. Pharmacoepidemiology. New York: John Wiley & Sons; 2000. p. 785-805.
10. Rothman KJ, Greenland S. Modern epidemiology. 2nd ed. Hagerstown (MD): Lippincott-Raven; 1998.
11. Kalden JR, Schattenkirchner M, Sorensen H, Emery P, Deighton C, Rozman B, et al. The efficacy and safety of leflunomide in patients with active rheumatoid arthritis: a five-year followup study. Arthritis Rheum 2003;48:1513-20.
12. Goldkind L, Simon LS. FDA meeting March 2003: update on the safety of new drugs for rheumatoid arthritis. Part III. Safety and efficacy update on leflunomide (Arava). URL: http://www. rheumatology.org/publications/hotline/ 05031effda.asp?aud=mem.
13. Cannon GW, Holden WL, Juhaeri J, Dai W, Scarazzini L, Stang P. Adverse events with disease modifying antirheumatic drugs (DMARD): a cohort study of leflunomide compared with other DMARD. J Rheumatol 2004;31:1906-11.
14. Cannon GW, Finck BK, the Enbrel ERA Investigator Group, Simpson KM, the Leflunomide Investigators Group, Strand V. Methotrexate-induced pulmonary disease during treatment of rheumatoid arthritis in large clinical trials [abstract]. Arthritis Rheum 2000;43 Suppl 9:S341.